Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India

Recently developed direct-acting antiviral (DAA) treatments for hepatitis C virus (HCV) have been groundbreaking for their high efficacy across disease genotypes and lack of severe side effects. This study uses a cost-of-illness (COI) approach to estimate the net value conferred by this class of dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Bloom, David E., Khoury, Alexander, Srinivasan, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297876/
https://www.ncbi.nlm.nih.gov/pubmed/34292958
http://dx.doi.org/10.1371/journal.pone.0252764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297876/
https://www.ncbi.nlm.nih.gov/pubmed/34292958
http://dx.doi.org/10.1371/journal.pone.0252764

Ejemplares similares